| Ytd | -13.35% | |
| 1y | 35.38% |
| Open | 27.15 | Prev Close | 27.26 | Low | 26.30 | High | 27.79 | Mkt Cap | 17.42M |
| Vol | 65.65K | Avg Vol | 26.61K | EPS | -16.60 | P/E | -1.62 | Forward P/E | N/A |
| Beta | 3.10 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 27.00 | 200-d Avg | 26.13 | 1yr Est | 0.00 |
PTHS News
Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing inno
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and r
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(3.09) per share which beat the analy
Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing inno
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and r
HC Wainwright & Co. analyst Brandon Folkes reiterates Pelthos Therapeutics (AMEX:PTHS) with a
Top analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, init